Cardiovascular & Cardiometabolic

Welcome to the Future of Early Health Screening: Introducing the ANS+ and CV+ Devices

Discover the ANS+ and CV+ Devices: A Revolution in Medical Screening Technology

The ANS+ device represents a groundbreaking advancement in the field of medical diagnostics. This innovative technology offers a non-invasive, quick, and efficient method to screen for a variety of health conditions, including diabetic neuropathy, cardiovascular autonomic neuropathy, and dysautonomia. The procedure is simple and takes only 7 to 10 minutes, making it an ideal choice for fast-paced medical environments.The CV+ (FDA Cleared) utilizes pulse-wave analysis technology. During this 3-minute test (non-invasive), the blood’s pulse wave is followed from the time it leaves the heart and travels through the blood vessels down to the finger providing a snapshot into the cardiovascular system.The Test Analyzes:

  • Overall Cardiovascular Health
  • Heart Rate Variability (HRV) and Mean Heart Rate
  • Autonomic Nervous System (ANS) Basic Markers
  • Overall Elasticity of Large, Small, and Peripheral Arteries (Arterial Stiffness)
  • Arteriosclerosis Progress
  • Mental Stress, Physical Stress, and Resistance to Stress
  • Hypertension

Comprehensive Health Assessments Supported by Insurance

One of the significant advantages of the ANS+ and CV+ devices is their coverage by major insurance providers. Medicare, Medicaid, and most commercial insurances offer reimbursement for the screenings provided by these devices, depending on state regulations. This wide coverage makes the ANS+ and CV+ devices accessible options for patients seeking early detection of potential health issues.

Key Features and Benefits of the ANS+ and CV+ Devices

  • Quick and Non-Invasive: Complete the ANS+ screening in just 7 to 10 minutes and the CV+ screening in 3 minutes with non-invasive procedures.
  • Broad Insurance Coverage: Screenings are reimbursed by Medicare, Medicaid, and most commercial insurances, subject to state-by-state regulations.
  • Early Detection: Capable of identifying conditions like diabetic neuropathy, cardiovascular autonomic neuropathy, and dysautonomia.
  • Enhanced Medical Practice: Implementing these devices in healthcare settings can significantly improve the management of medical instrument data, enhancing overall healthcare delivery.

Conclusion

The ANS+ and CV+ devices are not only tools for early detection but also means to enhance patient care through technology. They support healthcare providers by offering detailed assessments that are crucial for diagnosing various autonomic, cardiovascular, and other health conditions. The ease of use, combined with the support of insurance coverage, makes the ANS+ and CV+ devices valuable additions to any medical practice focusing on preventive care and early intervention.

The content on this page is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your qualified healthcare provider with any questions you may have regarding a medical condition. Reliance on any information provided herein is solely at your own risk.

Contact Us

To learn more about how the ANS+ device can benefit your practice, or to schedule a consultation, please contact us. Embrace the future of medical screening with the ANS+ device and take a significant step towards advanced healthcare solutions. By integrating the ANS+ device into your medical practice, you are not only enhancing the scope of your diagnostic capabilities but also ensuring that your patients receive the best preventive care possible. Join us in revolutionizing healthcare one screening at a time.